PharmaEssentia Corp
PharmaEssentia Corp., a leading biopharmaceutical company headquartered in Taiwan (TW), is dedicated to the development and commercialisation of innovative therapies for patients with rare diseases. Founded in 2003, the company has made significant strides in the industry, particularly in the fields of haematology and oncology. PharmaEssentia's flagship product, a novel treatment for essential thrombocythemia, exemplifies its commitment to addressing unmet medical needs with unique, scientifically-backed solutions. With a strong presence in Asia and expanding operations in global markets, PharmaEssentia has established itself as a key player in the biopharmaceutical landscape, recognised for its rigorous research and development efforts. The company continues to focus on delivering high-quality, effective therapies that improve patient outcomes and enhance quality of life.
DitchCarbon Score
How does PharmaEssentia Corp's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Medical Device Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
PharmaEssentia Corp's score of 17 is lower than 88% of the industry. This can give you a sense of how well the company is doing compared to its peers.
PharmaEssentia Corp's reported carbon emissions
In 2023, PharmaEssentia Corp reported total carbon emissions of approximately 4,374,400 kg CO2e, with Scope 2 emissions from purchased electricity accounting for about 2,905,970 kg CO2e. This marks a slight increase from 2022, where total emissions were around 4,264,600 kg CO2e. Over the years, the company has shown a gradual decrease in emissions, with 2019 emissions recorded at about 4,585,030 kg CO2e. PharmaEssentia's emissions data indicates a consistent focus on Scope 2 emissions, which have remained a significant portion of their total emissions. The company has not publicly disclosed specific reduction targets or initiatives under the Science Based Targets initiative (SBTi) or other climate pledges, suggesting a need for further commitment in this area. Overall, while PharmaEssentia has made progress in reducing its emissions over the years, the absence of formal reduction targets highlights an opportunity for the company to enhance its climate commitments and align with industry standards for sustainability.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
Add to project| 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|
| Scope 1 | - | - | - | - | - |
| Scope 2 | 3,055,000 | 0,000,000 | 0,000,000 | 0,000,000 | 0,000,000 |
| Scope 3 | 669,860 | - | - | - | - |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
PharmaEssentia Corp is not committed to any reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
